首页> 外国专利> MODULATORY LIPOSOMAL CONTROLLED RELEASE SYSTEM (MLCRS): A NEW DOSAGE FORM FOR ENCAPSULATING ANTICANCER DRUGS BASED ON LIPOSOMAL AND DENDRIMER TECHNOLOGY

MODULATORY LIPOSOMAL CONTROLLED RELEASE SYSTEM (MLCRS): A NEW DOSAGE FORM FOR ENCAPSULATING ANTICANCER DRUGS BASED ON LIPOSOMAL AND DENDRIMER TECHNOLOGY

机译:调节性脂质体控制释放系统(MLCRS):基于脂质体和树状体技术的抗癌药新剂量形式

摘要

Liposomes composed either of natural or synthetic phospholipids or either lipids or lipoamines or lipids. A dendrimer - anticancer drug complex or dendrimer - bioactive product complex encapsulated or attached to the lipid bilayers of the liposomes lead to a new liposomal form called Modulatory Liposomal Controlled Release System (MLCRS). This new liposomal was characterized physicochemicaly and the release rate of the anticancer drug doxorubicin was studied and corellated to the increase of the therapeutic index of doxorubicin. The advantage of this limposomal system is the modulation of the controlles release of the anticancer drug that is fundamental for the improvement of the pharmacokinetic parameters and its pharmacological evaluation. The present invention is suitable for use for the treatment of cancer.
机译:脂质体由天然或合成的磷脂或脂质或脂胺或脂质组成。封装或附着在脂质体脂质双层上的树状大分子-抗癌药物复合物或树状大分子-生物活性产物复合物导致一种新的脂质体形式,称为调节性脂质体控释系统(MLCRS)。对这种新脂质体进行了物理化学表征,研究了抗癌药物阿霉素的释放速率,并与阿霉素治疗指数的增加有关。该脂质体系统的优点是调节抗癌药物的控制释放,这是改善药代动力学参数及其药理学评估的基础。本发明适用于治疗癌症。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号